Prognostic role of glasgow prognostic score in patients with hepatocellular Carcinoma: A systematic review and meta-analysis

Medicine (United States)

Volumn 94, Issue 49, 2015, Pages

  Li, Mu Xing ^a   Bi, Xin Yu ^a   Li, Zhi Yu ^a   Huang, Zhen ^a   Han, Yue ^a   Zhou, Jian Guo ^a   Zhao, Jian Jun ^a   Zhang, Ye Fan ^a   Zhao, Hong ^a   Cai, Jian Qiang ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS ANTIBODY; C REACTIVE PROTEIN; SERUM ALBUMIN;

ARTICLE; ASSESSMENT OF HUMANS; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CHILD PUGH SCORE; FOLLOW UP; GLASGOW PROGNOSTIC SCORE; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SAMPLE SIZE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TUMOR INVASION; BLOOD; CARCINOMA, HEPATOCELLULAR; HEALTH STATUS INDICATOR; LIVER NEOPLASMS; MORTALITY; PROGNOSIS; SURVIVAL ANALYSIS;

C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; HEALTH STATUS INDICATORS; HUMANS; LIVER NEOPLASMS; PROGNOSIS; SERUM ALBUMIN; SURVIVAL ANALYSIS;

EID: 84952669400     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002133     Document Type: Article

References (42)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin. 2015;65:5-29.
2. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.
3. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61-74.
4. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocel-lular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918-928.
5. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751-755.
6. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224-1229.
7. Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759-771.
8. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
9. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med. 1966;123:365-378.
10. Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179-1186.
11. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534-540.
12. Dreanic J, Maillet M, Dhooge M, et al. Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies. Med Oncol. 2013;30:656.
13. Vashist YK, Loos J, Dedow J, et al. Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol. 2011;18:1130-1138.
14. Li QQ, Lu ZH, Yang L, et al. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev. 2014;15:945-950.
15. Mimatsu K, Oida T, Fukino N, et al. Glasgow prognostic score is a useful predictive factor of outcome after palliative gastrectomy for stage IV gastric cancer. Anticancer Res. 2014;34:3131-3136.
16. Horino K, Beppu T, Kuroki H, et al. Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma. Int J Clin Oncol. 2013;18:829-838.
17. Yamamura K, Sugimoto H, Kanda M, et al. Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. J Hepatobiliary Pancreat Sci. 2014;21:682-688.
18. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
19. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557-560.
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
22. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629-634.
23. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463.
24. Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803-810.
25. Fujiwara Y, Shiba H, Furukawa K, et al. Glasgow prognostic score is related to blood transfusion requirements and post-operative complications in hepatic resection for hepatocellular carcinoma. Anticancer Res. 2010;30:5129-5136.
26. Ni XC, Yi Y, Fu YP, et al. Prognostic value of the Modified Glasgow Prognostic Score in patients undergoing radical surgery for hepatocellular carcinoma. Medicine. 2015;94:e1486.
27. Chen YF, Ke Z, Zhou Y, et al. Primary discussion on prognostic value of Glasgow prognostic score in patients with primary hepatic carcinoma. J Clin Surg. 2015;22:568-570.
28. Kinoshita A, Onoda H, Imai N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 2012;107:988-993.
29. Kinoshita A, Onoda H, Imai N, et al. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:52.
30. Ishizuka M, Kubota K, Kita J, et al. Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. J Surg Oncol. 2011;103:801-806.
31. Ishizuka M, Kubota K, Kita J, et al. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepato-cellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg. 2012;203:101-106.
32. Morimoto M, Numata K, Moriya S, et al. Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. Anticancer Res. 2012;32:619-623.
33. Huang J, Xu L, Luo Y, et al. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31:883.
34. Pan QX, Zhang JH, Su ZJ, et al. The Glasgow Prognostic Score is an independent prognostic predictor of hepatocellular carcinoma following radical resection. Oncol Res Treat. 2014;37:192-197.
35. Okamura Y, Ashida R, Ito T, et al. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. World J Surg. 2015;39:1501-1509.
36. Zhou DS, Xu L, Luo YL, et al. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World J Gastroenterol. 2015;21:5582-5590.
37. Abe T, Tashiro H, Hattori M, et al. Prediction of long-term survival by using the Glasgow Prognostic Score in patients with hepatocel-lular carcinoma after liver transplantation. Hepatol Res. 2015. doi: 10.1111/hepr.12597. [Epub ahead of print].
38. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcino-genesis. 2009;30:1073-1081.
39. Zheng Z, Zhou L, Gao S, et al. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci. 2013;10:653-664.
40. Itoh S, Shirabe K, Matsumoto Y, et al. Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. Ann Surg Oncol. 2014;21:3063-3068.
41. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
42. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: Cancer J Clin. 2011;61:69-90.